Tau protein levels in the cerebrospinal fluid of the patients with multiple sclerosis in an attack period: Low levels of tau protein may have significance, too

2015 ◽  
Vol 136 ◽  
pp. 107-109 ◽  
Author(s):  
Gorkem Kosehasanogullari ◽  
Serkan Ozakbas ◽  
Egemen Idiman
2007 ◽  
Vol 115 (5) ◽  
pp. 325-330 ◽  
Author(s):  
M. Terzi ◽  
A. Birinci ◽  
E. Çetinkaya ◽  
M. K. Onar

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ellen F. Mosleth ◽  
Christian Alexander Vedeler ◽  
Kristian Hovde Liland ◽  
Anette McLeod ◽  
Gerd Haga Bringeland ◽  
...  

AbstractDespite intensive research, the aetiology of multiple sclerosis (MS) remains unknown. Cerebrospinal fluid proteomics has the potential to reveal mechanisms of MS pathogenesis, but analyses must account for disease heterogeneity. We previously reported explorative multivariate analysis by hierarchical clustering of proteomics data of MS patients and controls, which resulted in two groups of individuals. Grouping reflected increased levels of intrathecal inflammatory response proteins and decreased levels of proteins involved in neural development in one group relative to the other group. MS patients and controls were present in both groups. Here we reanalysed these data and we also reanalysed data from an independent cohort of patients diagnosed with clinically isolated syndrome (CIS), who have symptoms of MS without evidence of dissemination in space and/or time. Some, but not all, CIS patients had intrathecal inflammation. The analyses reported here identified a common protein signature of MS/CIS that was not linked to elevated intrathecal inflammation. The signature included low levels of complement proteins, semaphorin-7A, reelin, neural cell adhesion molecules, inter-alpha-trypsin inhibitor heavy chain H2, transforming growth factor beta 1, follistatin-related protein 1, malate dehydrogenase 1 cytoplasmic, plasma retinol-binding protein, biotinidase, and transferrin, all known to play roles in neural development. Low levels of these proteins suggest that MS/CIS patients suffer from abnormally low oxidative capacity that results in disrupted neural development from an early stage of the disease.


2000 ◽  
Vol 43 (4) ◽  
pp. 228-232 ◽  
Author(s):  
Elisabeth Kapaki ◽  
George P. Paraskevas ◽  
Maria Michalopoulou ◽  
Konstantinos Kilidireas

2012 ◽  
Vol 18 (8) ◽  
pp. 1081-1091 ◽  
Author(s):  
Timucin Avsar ◽  
Didem Korkmaz ◽  
Melih Tütüncü ◽  
N Onat Demirci ◽  
Sabahattin Saip ◽  
...  

Background: The complex pathogenesis of multiple sclerosis, combined with an unpredictable prognosis, requires identification of disease-specific diagnostic and prognostic biomarkers. Objective: To determine whether inflammatory proteins, such as neurofilament light chain, myelin oligodendrocyte glycoprotein and myelin basic protein, and neurodegenerative proteins, such as tau and glial fibrillary acidic protein, can serve as biomarkers for predicting the clinical subtype and prognosis of MS. Methods: Cerebrospinal fluid and serum samples were collected from patients with a diagnosis of clinically isolated syndrome ( n = 46), relapsing–remitting MS ( n = 67) or primary-progressive MS ( n = 22) along with controls having other non-inflammatory neurological disease ( n = 22). Western blot analyses were performed for the listed proteins. Protein levels were compared among different clinical subtypes using one-way analysis of variance analysis. The k-nearest neighbour algorithm was further used to assess the predictive use of these proteins for clinical subtype classification. Results: The results showed that each of tau, GFAP, MOG and NFL protein concentrations differed significantly ( p < 0.001) in multiple sclerosis clinical subtypes compared with the controls. Levels of the proteins also differed between the multiple sclerosis clinical subtypes, which may be associated with the underlying disease process. Classification studies revealed that these proteins might be useful for identifying multiple sclerosis clinical subtypes. Conclusions: We showed that select biomarkers may have potential in identifying multiple sclerosis clinical subtypes. We also showed that the predictive value of the prognosis increased when using a combination of the proteins versus using them individually.


1998 ◽  
Vol 256 (3) ◽  
pp. 174-176 ◽  
Author(s):  
Hiroyuki Arai ◽  
Takuma Satoh-Nakagawa ◽  
Makoto Higuchi ◽  
Yu-ichi Morikawa ◽  
Masakazu Miura ◽  
...  

2004 ◽  
Vol 363 (1) ◽  
pp. 14-17 ◽  
Author(s):  
Antonio Martı́nez-Yélamos ◽  
Albert Saiz ◽  
Jordi Bas ◽  
Juan Jose Hernandez ◽  
Francesc Graus ◽  
...  

Author(s):  
Shivanjali Sood ◽  
Chandrika Azad ◽  
Jasbinder Kaur ◽  
Pankaj Kumar ◽  
Vishal Guglani ◽  
...  

Author(s):  
K.G. Warren ◽  
P.A. Gordon ◽  
T.A. McPherson

SUMMARY:A 17-year old female with “malignant” multiple sclerosis died 45 weeks after the onset of the disease. Postmortem examination confirmed the clinical diagnosis of multiple sclerosis. After 30 weeks of rapid clinical progression, the patient was treated with two courses of plasma exchange therapy without immunosuppression. This form of therapy caused a drop in cerebrospinal fluid myelin basic protein levels in one instance, but not in another. Controlled clinical trials are required to determine whether plasma exchange therapy is of value in the management of patients with multiple sclerosis, and the monitoring of cerebrospinal fluid myelin basic protein, if elevated, may be one useful marker to follow as part of these studies.


Sign in / Sign up

Export Citation Format

Share Document